TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38176879

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 6480

Group type: COMPARATOR
Intervention: Usual care (not offering telemedicine)
Number of subjects: 6480
Study: 38176899

Group type: EXPERIMENTAL
Intervention: Blood-based CRC test (Shield, Guardant Health)
Number of subjects: 2004

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2004
Study: 38177042

Group type: EXPERIMENTAL
Intervention: Second autologous hematopoietic stem cell transplantation (aHSCT)
Number of subjects: 4
Study: 38177091

Group type: EXPERIMENTAL
Intervention: Predictive Alarm (PA) for hypoglycaemia
Number of subjects: 20
Study: 38177116

Group type: EXPERIMENTAL
Intervention: RIV4
Number of subjects: 1407

Group type: EXPERIMENTAL
Intervention: RIV4 or ccIIV4
Number of subjects: 1407

Group type: COMPARATOR
Intervention: IIV4, ccIIV4, RIV4
Number of subjects: 1407
Study: 38177128

Group type: EXPERIMENTAL
Intervention: Post-exertional malaise induction in patients with long COVID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 38177178

Group type: EXPERIMENTAL
Intervention: High platelet reactivity (PRU ≥ 252)
Number of subjects: 11714

Group type: EXPERIMENTAL
Intervention: High aspirin reaction unit (≥ 414)
Number of subjects: 11714

Group type: EXPERIMENTAL
Intervention: Early stent thrombosis (EST) group
Number of subjects: 11714

Group type: COMPARATOR
Intervention: Non-EST group
Number of subjects: 11714
Study: 38177509

Group type: EXPERIMENTAL
Intervention: Core stability exercises
Number of subjects: 52

Group type: COMPARATOR
Intervention: Rebound therapy
Number of subjects: 52
Study: 38177554

Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Non-surgical controls (NS)
Number of subjects: 46
Study: 38177805

Group type: EXPERIMENTAL
Intervention: semaglutide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: dapagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 38177851

Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine
Number of subjects: 726

Group type: COMPARATOR
Intervention: Praziquantel (standard care)
Number of subjects: 726
Study: 38177853

Group type: EXPERIMENTAL
Intervention: Sotorasib plus panitumumab
Number of subjects: 0
Study: 38177852

Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin plus pomalidomide and dexamethasone
Number of subjects: 87
Study: 38177855

Group type: EXPERIMENTAL
Intervention: bidridistrogene xeboparvovec, an adeno-associated virus-based gene therapy
Number of subjects: 0
Study: 38177986

Group type: COMPARATOR
Intervention: Gut microbiota composition analysis using Shannon index, Simpson index, principal coordinates analysis, and Wilcoxon rank-sum test.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Plasma concentrations of tryptophan metabolites compared using t tests and analysis of variance.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ratio of kynurenic acid to quinolinic acid evaluated using receiver operating characteristic curve.
Number of subjects: 33
Study: 38178036

Group type: EXPERIMENTAL
Intervention: Cochlear Implantation
Number of subjects: 100
Study: 38178048

Group type: EXPERIMENTAL
Intervention: Treatment modalities for SE
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: EEG data collection
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Factors associated with outcome and refractoriness
Number of subjects: 3000
Study: 38178051

Group type: EXPERIMENTAL
Intervention: Orthopaedic Manipulation Techniques of LSLR (OMT-LSLR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham manipulation treatment
Number of subjects: 50
Study: 38178156

Group type: EXPERIMENTAL
Intervention: Fistula repair surgery
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Qualitative inquiry with key stakeholders
Number of subjects: 1000
Study: 38178168

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propofol and sufentanil in combination (P + S)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propofol and esketamine in combination (P + K)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propofol and lidocaine in combination (P + L)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Esketamine with propofol
Number of subjects: 100
Study: 38178180

Group type: EXPERIMENTAL
Intervention: One-point fixation at zygomaticomaxillary buttress
Number of subjects: 0
Study: 38178223

Group type: EXPERIMENTAL
Intervention: Probiotics (Bifidobacterium lactis BI040, B. longum BL020, Lactobacillus rhamnosus LR110, L. casei LC130, L. acidophilus LA120, 5 billion CFU total)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 38178229

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D
Number of subjects: 307
Study: 38178233

Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate (OROS-MPH)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 38178267

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) provided by physical therapists for 12 weeks
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mirabegron for 12 weeks
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Trospium chloride for 12 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: All interventions (PFMT, mirabegron, trospium)
Number of subjects: 48
Study: 38178318

Group type: COMPARATOR
Intervention: NST device volume turned off (Control)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: NST device volume 1-35 dB(A)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: NST device volume 36-60 dB(A)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: NST device volume 61 dB(A) and above
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: All intervention groups (1-35 dB(A), 36-60 dB(A), 61 dB(A) and above)
Number of subjects: 44
Study: 38178322

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) application via virtual glasses during pelvic examination
Number of subjects: 128

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 128
Study: 38178557

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: IL-1ra
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 38178863

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38178887

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) for acute basilar artery occlusion (BAO)
Number of subjects: 185
Study: 38179107

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 38179189

Group type: EXPERIMENTAL
Intervention: 3T MR scanner
Number of subjects: 26
Study: 38179309

Group type: EXPERIMENTAL
Intervention: Unintentional changes in body mass index (BMI)
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Unintentional changes in waist circumference (WC)
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Third tertiles of BMI change
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Third tertiles of WC change
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Stable BMI and WC
Number of subjects: 10251
Study: 38179809

Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg
Number of subjects: 525
Study: 38179936

Group type: EXPERIMENTAL
Intervention: Moderate low-dose radiotherapy, dosage and duration not available
Number of subjects: 0
Study: 38180092

Group type: EXPERIMENTAL
Intervention: Intra-arrest crS o2 monitoring during cardiopulmonary resuscitation
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Higher crS o2 during CPR
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Higher crS o2 during CPR in infants (< 1 yr)
Number of subjects: 123
Study: 38180230

Group type: EXPERIMENTAL
Intervention: Children admitted for COVID-19
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Children hospitalized for COVID-19
Number of subjects: 36
Study: 38180268

Group type: COMPARATOR
Intervention: Disulfiram
Number of subjects: 1191
Study: 38180338

Group type: EXPERIMENTAL
Intervention: Multiparametric breast MRI (including DWI and DCE MRI)
Number of subjects: 191
Study: 38180348

Group type: EXPERIMENTAL
Intervention: Modified ride-on car (ROC) with standing for 70 min
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Modified ride-on car (ROC) with various postural combinations
Number of subjects: 19
Study: 38180893

Group type: EXPERIMENTAL
Intervention: CMV IgG titer
Number of subjects: 717
Study: 38180983

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (CTX) 1 gr/day for up to 7 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 38181004

Group type: EXPERIMENTAL
Intervention: Problem-Management Plus and 'Thinking Healthy' interventions combined with specific parts of the Strong Minds-Strong Communities intervention
Number of subjects: 265

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 265
Study: 38181048

Group type: EXPERIMENTAL
Intervention: IIV-AS03
Number of subjects: 20

Group type: COMPARATOR
Intervention: IIV
Number of subjects: 20
Study: 38181311

Group type: EXPERIMENTAL
Intervention: Ticagrelor plus aspirin
Number of subjects: 6412

Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin
Number of subjects: 6412
Study: 38181312

Group type: EXPERIMENTAL
Intervention: Cetuximab plus Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI/Cet)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Cetuximab alone (Control)
Number of subjects: 606
Study: 38181433

Group type: EXPERIMENTAL
Intervention: BMMNC treatment
Number of subjects: 47
Study: 38181547

Group type: EXPERIMENTAL
Intervention: Hospital involvement in COVID-19-related care
Number of subjects: 100
Study: 38181724

Group type: EXPERIMENTAL
Intervention: Levcromakalim (0.05 mg/ml infusion)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 38181782

Group type: EXPERIMENTAL
Intervention: Intravenous high-dose methotrexate (MTX) 1.5 g/m2 after 6 cycles of R-CHOP regimen; IT liposomal cytarabine administered on day 0 of cycles 2 to 5 of R-CHOP; contralateral testis radiotherapy (25-30 Gy) recommended.
Number of subjects: 54

Group type: COMPARATOR
Intervention: R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, every 21 days).
Number of subjects: 54
Study: 38181784

Group type: EXPERIMENTAL
Intervention: SCD pre-HSCT
Number of subjects: 20

Group type: COMPARATOR
Intervention: SCD post-HSCT
Number of subjects: 20

Group type: COMPARATOR
Intervention: HbAS
Number of subjects: 20

Group type: COMPARATOR
Intervention: HbAA
Number of subjects: 20
Study: 38181791

Group type: EXPERIMENTAL
Intervention: Olgotrelvir (STI-1558)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AC1115 (active form of Olgotrelvir)
Number of subjects: 0
Study: 38181795

Group type: EXPERIMENTAL
Intervention: serplulimab 4.5 mg/kg plus nab-paclitaxel and carboplatin
Number of subjects: 537

Group type: COMPARATOR
Intervention: placebo plus nab-paclitaxel and carboplatin
Number of subjects: 537
Study: 38181820

Group type: EXPERIMENTAL
Intervention: Approach-oriented coping
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Avoidant coping
Number of subjects: 360
Study: 38181882

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (sleeve gastrectomy and Roux-en-Y gastric bypass)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (RYGB)
Number of subjects: 28
Study: 38182130

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38182406

Group type: EXPERIMENTAL
Intervention: Deep immunophenotyping using 13 flow cytometry panels
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Unsupervised clustering
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Principal component analysis
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: First axis driven by the ratio of LAG3+ to ICOS+ in regulatory T lymphocytes (Tregs)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Second axis driven by activated Tregs and type 3 innate lymphoid cells (ILC3s)
Number of subjects: 443
Study: 38182456

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT) with tPA
Number of subjects: 221

Group type: COMPARATOR
Intervention: No intravenous thrombolysis (no IVT)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 221
Study: 38182483

Group type: EXPERIMENTAL
Intervention: Online breastfeeding education
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 50
Study: 38182687

Group type: EXPERIMENTAL
Intervention: Everolimus plus exemestane
Number of subjects: 150
Study: 38182784

Group type: EXPERIMENTAL
Intervention: Magnesium-Ibogaine therapy
Number of subjects: 30
Study: 38182785

Group type: EXPERIMENTAL
Intervention: Ripretinib 150 mg once daily
Number of subjects: 362

Group type: COMPARATOR
Intervention: Sunitinib 50 mg
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Ripretinib 150 mg
Number of subjects: 362
Study: 38182792

Group type: EXPERIMENTAL
Intervention: SAGA intervention (Social Games for Autistic Adolescents)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 0
Study: 38182919

Group type: EXPERIMENTAL
Intervention: Exergames Program (EP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional Exercise Program (CP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of EP vs CP
Number of subjects: 20
Study: 38182920

Group type: EXPERIMENTAL
Intervention: Advanced characterization of serum glycoprotein and lipoprotein profile measured by proton nuclear magnetic resonance spectroscopy
Number of subjects: 323
Study: 38183045

Group type: EXPERIMENTAL
Intervention: Neuromuscular joint-protective exercise therapy program
Number of subjects: 48

Group type: COMPARATOR
Intervention: Training program with ROM exercises
Number of subjects: 48
Study: 38183047

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Cardiac Surgery (ERACS) bundle strategy including preoperative, intraoperative, and postoperative approaches.
Number of subjects: 3030

Group type: COMPARATOR
Intervention: Usual care during the control phase.
Number of subjects: 3030
Study: 38183062

Group type: EXPERIMENTAL
Intervention: Vitamin E-enriched medium cross-linked polyethylene (MXE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard polyethylene gliding surface
Number of subjects: 0
Study: 38183067

Group type: EXPERIMENTAL
Intervention: Health services used in Denmark (consultations at outpatient clinics, visits to general practitioners, visits to fitness centres)
Number of subjects: 3417

Group type: COMPARATOR
Intervention: Health services used in Norway (visits to general practitioners, rehospitalisation, no follow-up)
Number of subjects: 3417

Group type: EXPERIMENTAL
Intervention: Perceived need for follow-up and information
Number of subjects: 3417
Study: 38183081

Group type: EXPERIMENTAL
Intervention: 20% propolis mouthwash
Number of subjects: 144

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine mouthwash
Number of subjects: 144
Study: 38183089

Group type: EXPERIMENTAL
Intervention: Breaking the Cycle intervention program
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Maxxine Wright intervention program
Number of subjects: 100
Study: 38183121

Group type: EXPERIMENTAL
Intervention: Dog present but not integrated in the therapeutic narrative
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dog actively integrated in the therapeutic narrative
Number of subjects: 150

Group type: COMPARATOR
Intervention: No dog present
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Therapists' evaluations
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Treatment adherence
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Treatment satisfaction
Number of subjects: 150
Study: 38183137

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 240
Study: 38183154

Group type: EXPERIMENTAL
Intervention: Telehealth delivery of nonpharmacologic care from physical therapists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation strategies focusing on training, education, clinician support, and tailoring physical therapy interventions for telehealth delivery and cultural competency
Number of subjects: 0
Study: 38183273

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Evolocumab with statin and/or ezetimibe
Number of subjects: 75

Group type: COMPARATOR
Intervention: Evolocumab alone
Number of subjects: 75
Study: 38183497

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg intravenous preoperatively)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg in initial irrigation fluid)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no tranexamic acid)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (both groups)
Number of subjects: 75
Study: 38183525

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) in a treat-and-extend (T&E) regimen (n=168)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Intravitreal aflibercept (IVT-AFL) fixed dosing regimen (n=168)
Number of subjects: 332
Study: 38183526

Group type: EXPERIMENTAL
Intervention: CTC 100 mg (44 mg rac-tramadol hydrochloride/56 mg celecoxib; n=164)
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: CTC 150 mg (66 mg rac-tramadol hydrochloride/84 mg celecoxib; n=160)
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: CTC 200 mg (88 mg rac-tramadol hydrochloride/112 mg celecoxib; n=160)
Number of subjects: 726

Group type: COMPARATOR
Intervention: Tramadol 100 mg four times daily (n=159)
Number of subjects: 726

Group type: COMPARATOR
Intervention: Placebo four times daily (n=83)
Number of subjects: 726
Study: 38183804

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for insomnia (CBT-I)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Sham Quasi-Desensitization Therapy for Insomnia (DTI)
Number of subjects: 108
Study: 38184008

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg twice daily for 7 days
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study: 38184303

Group type: EXPERIMENTAL
Intervention: CMV-targeting T cell receptor-engineered T (CMV-TCR-T) cell therapy, administered in 1 to 3 doses.
Number of subjects: 6
Study: 38184304

Group type: EXPERIMENTAL
Intervention: VB-111 (ofranergene obadenovec) and nivolumab
Number of subjects: 14
Study: 38184414

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control isotype
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Preclinical model with anti-PD-1 antibody
Number of subjects: 42
Study: 38184428

Group type: EXPERIMENTAL
Intervention: avalglucosidase alfa
Number of subjects: 99

Group type: COMPARATOR
Intervention: alglucosidase alfa
Number of subjects: 99
Study: 38184475

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention consisting of short video lectures on obesity, vignettes simulating interactions with PwO, and open discourse with a PwO.
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group received a short-written document on obesity.
Number of subjects: 162
Study: 38184489

Group type: EXPERIMENTAL
Intervention: HSK7653
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (normal renal function)
Number of subjects: 42
Study: 38184491

Group type: EXPERIMENTAL
Intervention: Supervised Home Exercise Group (SHEG)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Home Exercise Group (HEG)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 45
Study: 38184507

Group type: EXPERIMENTAL
Intervention: Macitentan, initiated as combination therapy in 74.8% of patients, median exposure 11.9 months (Q1, Q3: 3.1, 26.0)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Macitentan
Number of subjects: 206
Study: 38184559

Group type: EXPERIMENTAL
Intervention: Brief physical activity and diet intervention (PACE)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Healthcare provider training and support
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Individualized approach to intervention
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Contextual factors (e.g., COVID-19 pandemic)
Number of subjects: 25
Study: 38184582

Group type: COMPARATOR
Intervention: SGLT-2i
Number of subjects: 443

Group type: COMPARATOR
Intervention: GLP-1RA
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: SGLT-2i/GLP-1RA combination therapy
Number of subjects: 443
Study: 38184633

Group type: EXPERIMENTAL
Intervention: Integration of smoking cessation interventions at outpatient OAT clinics, including weekly follow-up, a short behavioural intervention, and provision of nicotine replacement products.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (control group).
Number of subjects: 0
Study: 38184642

Group type: EXPERIMENTAL
Intervention: In-person cognitive behavioral therapy (CBT)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3
Study: 38184737

Group type: EXPERIMENTAL
Intervention: Kidney BEAM intervention
Number of subjects: 42

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 42
Study: 38184920

Group type: EXPERIMENTAL
Intervention: Pegvaliase treatment
Number of subjects: 250
Study: 38184927

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) using the Epic Roller Coasters application
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no distraction method)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 69
Study: 38185111

Group type: EXPERIMENTAL
Intervention: Usual care and outpatient comprehensive geriatric care (CGC) clinic
Number of subjects: 53

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 53
Study: 38185283

Group type: EXPERIMENTAL
Intervention: Type 2 myocardial infarction (T2MI)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Type 1 myocardial infarction (T1MI)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: T2MI
Number of subjects: 194
Study: 38185496

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0